(Reuters) - Drugmaker Endo International Plc on Wednesday posted a fourth-quarter profit that beat analysts' estimates, getting a boost from higher sales in its sterile injectables unit. The generic drugmaker, which faces mounting expenses from lawsuits that seek to hold it responsible for fueling the U.S. opioid crisis, has shifted focus to other units such as medical aesthetics to cushion the blow of lower generic drug prices. The company's shares were up 4% at $6.81 in premarket trade. Endo said it expects 2020 profit between $2.15 and $2.40 per share. Fourth-quarter revenue at its sterile injectables unit, which includes blood pressure shot Vasostrict, rose 10% to $285.2 million.

Source: International New York Times February 26, 2020 11:37 UTC